CD4 and metastatic neoplasm: Notably, one study identified BRAFV600E-specific CD4+ T cells after repetitive peptide stimulation of peripheral blood mononuclear cells from three melanoma patients whose metastatic tumors harbored the BRAFV600E mutation (40).